Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 3/20 | 0.45 |
| ▸ | SORD | Q00796 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17845040 | 0.82 | HRH4 (0.53) | DRD2DRD4HRH4DRD3SORD | |
| SCHEMBL17861451 | 0.82 | DRD2 (0.60) | DRD2DRD4HRH4DRD3 | |
| SCHEMBL1532949 | 0.80 | DRD2 (0.50) | DRD2DRD4HRH4DRD3ACHE | |
| SCHEMBL13139591 | 0.77 | HRH3 (0.51) | DRD4 | |
| SCHEMBL1255986 | 0.76 | ACHE (0.59) | HRH4SORDACHE | |
| SCHEMBL9224900 | 0.75 | HRH4 (0.63) | DRD2DRD4HRH4DRD3SORD | |
| SCHEMBL2587527 | 0.74 | HRH3 (0.36) | DRD2DRD4DRD3 | |
| SCHEMBL17847528 | 0.74 | DRD2 (0.55) | DRD2DRD4HRH4DRD3SORD | |
| SCHEMBL8134047 | 0.73 | HRH4 (0.64) | DRD2DRD4HRH4DRD3SORD | |
| SCHEMBL17847547 | 0.73 | DRD2 (0.62) | DRD2DRD4HRH4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10369130-B2 | Antibacterial compounds | AZIEN DE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 2019-08-06 | — | — | US | disclosed |
| US-20170368017-A1 | ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-12-28 | — | — | US | disclosed |
| WO-2016096631-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10369130-B2 | Antibacterial compounds | MRPL21, CLPP, NRDC | DRD2 3384/4885DRD4 1835/4885HRH4 3610/4885 |
| US-20170368017-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, CLPP, NRDC | DRD2 3384/4885DRD4 1835/4885HRH4 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.